GURUFOCUS.COM » STOCK LIST » Healthcare » Biotechnology » Lisata Therapeutics Inc (NAS:LSTA) » Definitions » Cyclically Adjusted PB Ratio

LSTA (Lisata Therapeutics) Cyclically Adjusted PB Ratio : 0.06 (As of May. 29, 2025)


View and export this data going back to 1999. Start your Free Trial

What is Lisata Therapeutics Cyclically Adjusted PB Ratio?

As of today (2025-05-29), Lisata Therapeutics's current share price is $2.6798. Lisata Therapeutics's Cyclically Adjusted Book per Share for the quarter that ended in Mar. 2025 was $46.59. Lisata Therapeutics's Cyclically Adjusted PB Ratio for today is 0.06.

The historical rank and industry rank for Lisata Therapeutics's Cyclically Adjusted PB Ratio or its related term are showing as below:

LSTA' s Cyclically Adjusted PB Ratio Range Over the Past 10 Years
Min: 0.01   Med: 0.06   Max: 0.61
Current: 0.06

During the past years, Lisata Therapeutics's highest Cyclically Adjusted PB Ratio was 0.61. The lowest was 0.01. And the median was 0.06.

LSTA's Cyclically Adjusted PB Ratio is ranked better than
91.64% of 670 companies
in the Biotechnology industry
Industry Median: 1.485 vs LSTA: 0.06

The Shiller PE Ratio was first used by professor Robert Shiller. He uses E10 for his Shiller PE Ratio calculation. E10 is the average of the inflation adjusted earnings per share of a company over the past 10 years. The similar calculation is applied by GuruFocus to calculate the Cyclically Adjusted PB Ratio. The Cyclically Adjusted Book per Share is the average of the inflation adjusted book value per share of a company over the past 10 years.

Lisata Therapeutics's adjusted book value per share data for the three months ended in Mar. 2025 was $2.942. Add all the adjusted book value per share for the past 10 years together and divide the count will get our Cyclically Adjusted Book per Share, which is $46.59 for the trailing ten years ended in Mar. 2025.

Shiller PE for Stocks: The True Measure of Stock Valuation


Lisata Therapeutics Cyclically Adjusted PB Ratio Historical Data

The historical data trend for Lisata Therapeutics's Cyclically Adjusted PB Ratio can be seen below:

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

* Premium members only.

Lisata Therapeutics Cyclically Adjusted PB Ratio Chart

Lisata Therapeutics Annual Data
Trend Dec15 Dec16 Dec17 Dec18 Dec19 Dec20 Dec21 Dec22 Dec23 Dec24
Cyclically Adjusted PB Ratio
Get a 7-Day Free Trial Premium Member Only Premium Member Only 0.08 0.07 0.02 0.03 0.06

Lisata Therapeutics Quarterly Data
Jun20 Sep20 Dec20 Mar21 Jun21 Sep21 Dec21 Mar22 Jun22 Sep22 Dec22 Mar23 Jun23 Sep23 Dec23 Mar24 Jun24 Sep24 Dec24 Mar25
Cyclically Adjusted PB Ratio Get a 7-Day Free Trial Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only 0.04 0.05 0.05 0.06 0.05

Competitive Comparison of Lisata Therapeutics's Cyclically Adjusted PB Ratio

For the Biotechnology subindustry, Lisata Therapeutics's Cyclically Adjusted PB Ratio, along with its competitors' market caps and Cyclically Adjusted PB Ratio data, can be viewed below:

* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.


Lisata Therapeutics's Cyclically Adjusted PB Ratio Distribution in the Biotechnology Industry

For the Biotechnology industry and Healthcare sector, Lisata Therapeutics's Cyclically Adjusted PB Ratio distribution charts can be found below:

* The bar in red indicates where Lisata Therapeutics's Cyclically Adjusted PB Ratio falls into.


;
;

Lisata Therapeutics Cyclically Adjusted PB Ratio Calculation

Like the Shiller PE Ratio, the Cyclically Adjusted PB Ratio takes the Book Value per Share from the past 10 years, adjusts it for inflation, and then calculates the average. This average is then used for the P/B calculation. Because it considers this 10-year average, it's often referred to as the CAPB Ratio.

The Shiller PE Ratio was first used by professor Robert Shiller to measure the valuation of the overall market. The similar calculation is applied by GuruFocus to calculate the Cyclically Adjusted PB Ratio.

Lisata Therapeutics's Cyclically Adjusted PB Ratio for today is calculated as

Cyclically Adjusted PB Ratio=Share Price/ Cyclically Adjusted Book per Share
=2.6798/46.59
=0.06

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

Lisata Therapeutics's Cyclically Adjusted Book per Share for the quarter that ended in Mar. 2025 is calculated as:

For example, Lisata Therapeutics's adjusted Book Value per Share data for the three months ended in Mar. 2025 was:

Adj_Book=Book Value per Share/CPI of Mar. 2025 (Change)*Current CPI (Mar. 2025)
=2.942/134.9266*134.9266
=2.942

Current CPI (Mar. 2025) = 134.9266.

Lisata Therapeutics Quarterly Data

Book Value per Share CPI Adj_Book
201506 179.411 100.684 240.429
201509 149.808 100.392 201.343
201512 62.735 99.792 84.822
201603 34.675 100.470 46.567
201606 15.316 101.688 20.322
201609 19.717 101.861 26.117
201612 8.945 101.863 11.848
201703 -1.325 102.862 -1.738
201706 91.618 103.349 119.611
201709 84.925 104.136 110.036
201712 79.916 104.011 103.670
201803 71.455 105.290 91.568
201806 67.500 106.317 85.664
201809 62.625 106.507 79.336
201812 57.334 105.998 72.981
201903 50.113 107.251 63.045
201906 43.130 108.070 53.849
201909 36.380 108.329 45.312
201912 29.652 108.420 36.901
202003 24.320 108.902 30.132
202006 32.542 108.767 40.369
202009 29.188 109.815 35.863
202012 25.152 109.897 30.881
202103 27.796 111.754 33.559
202106 26.445 114.631 31.127
202109 24.760 115.734 28.866
202112 23.145 117.630 26.548
202203 21.926 121.301 24.389
202206 20.399 125.017 22.016
202209 9.160 125.227 9.870
202212 8.428 125.222 9.081
202303 7.622 127.348 8.076
202306 7.128 128.729 7.471
202309 6.507 129.860 6.761
202312 5.908 129.419 6.159
202403 5.176 131.776 5.300
202406 4.597 132.554 4.679
202409 4.049 133.029 4.107
202412 3.517 133.157 3.564
202503 2.942 134.927 2.942

Add all the adjusted book value per share together and divide the count will get our Cyclically Adjusted Book per Share.

Please note that we use the CPI data of the country/region where the company is headquartered. If the CPI data for that country/region is not available, then we will use the CPI data of the United States as default.


Lisata Therapeutics  (NAS:LSTA) Cyclically Adjusted PB Ratio Explanation

Compared with the regular PB Ratio, which works poorly for cyclical businesses, the Cyclically Adjusted PB Ratio smoothed out the fluctuations of book value during business cycles. Therefore it is more accurate in reflecting the valuation of the company.

If a company has consistent business performance, the Cyclically Adjusted PB Ratio should give similar results to regular PB Ratio.


Lisata Therapeutics Cyclically Adjusted PB Ratio Related Terms

Thank you for viewing the detailed overview of Lisata Therapeutics's Cyclically Adjusted PB Ratio provided by GuruFocus.com. Please click on the following links to see related term pages.


Lisata Therapeutics Business Description

Traded in Other Exchanges
Address
110 Allen Road, 2nd Floor, Basking Ridge, NJ, USA, 07920
Lisata Therapeutics Inc is a clinical-stage pharmaceutical company dedicated to the discovery, development, and commercialization of therapies for the treatment of solid tumors and other diseases. Its investigational product, certepetide, is designed to activate a novel uptake pathway that allows co-administered or tethered (i.e., molecularly bound) anti-cancer drugs to target and penetrate solid tumors more effectively. The group has one operating segment, the research and development of its investigational drug product.
Executives
David W. Slack director, officer: President & CBO 110 ALLEN ROAD, 2ND FLOOR, BASKING RIDGE NJ 07920
Heidi Henson director 2173 SALK AVENUE, SUITE 250, PMB#052, CARLSBAD CA 92008
Mohammad Azab director C/O SUPERGEN, INC., 4140 DUBLIN BLVD., SUITE 200, DUBLIN CA 94568
Erkki Ruoslahti director P.O. BOX 544, BUELLTON CA 93427
Steven S Myers director 4695 MACAUTHUR COURT, EIGHTH FLOOR, NEWPORT BEACH CA 92660
Kristen K Buck officer: EVP, R&D and CMO 110 ALLEN ROAD, 2ND FLOOR, BASKING RIDGE NJ 07920
Todd C Girolamo officer: CLO, SVP of Corp Dev 110 ALLEN ROAD, 2ND FLOOR, BASKING RIDGE NJ 07920
Anne Clem Whitaker director 109 BRIERY BRANCH COURT, MORRISVILLE NC 27560
Michael H. Davidson director OMTHERA PHARMACEUTICALS, INC., 707 STATE ROAD, PRINCETON NJ 08540
Cynthia Schwalm director C/O G1 THERAPEUTICS, 700 PARK OFFICES DR, SUITE 200, P.O. BOX 110341, RESEARCH TRIANGLE PARK NC 27709
David J Mazzo director, officer: Chief Executive Officer 110 ALLEN ROAD, 2ND FLOOR, BASKING RIDGE NJ 07920
Joseph Talamo officer: SVP and CFO CALADRIUS BIOSCIENCES, INC., 800 WESTCHESTER AVENUE. STE N341, RYE BROOK NY 10573
Douglas W Losordo officer: See Remarks 13 FOX MEADOW RD, SCARSDALE NY 10583
Anford 10 percent owner P.O. BOX 5039, SIOUX FALLS SD 57117
Health Sanford 10 percent owner P.O. BOX 5039, SIOUX FALLS SD 57117